NZ582327A - Pharmaceutical combination of nsaid and prostaglandin compound - Google Patents

Pharmaceutical combination of nsaid and prostaglandin compound

Info

Publication number
NZ582327A
NZ582327A NZ582327A NZ58232708A NZ582327A NZ 582327 A NZ582327 A NZ 582327A NZ 582327 A NZ582327 A NZ 582327A NZ 58232708 A NZ58232708 A NZ 58232708A NZ 582327 A NZ582327 A NZ 582327A
Authority
NZ
New Zealand
Prior art keywords
nsaid
disclosed
acid
compound
diseases
Prior art date
Application number
NZ582327A
Other languages
English (en)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of NZ582327A publication Critical patent/NZ582327A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ582327A 2007-07-03 2008-07-03 Pharmaceutical combination of nsaid and prostaglandin compound NZ582327A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92955707P 2007-07-03 2007-07-03
US3751708P 2008-03-18 2008-03-18
PCT/JP2008/062437 WO2009005172A1 (en) 2007-07-03 2008-07-03 Pharmaceutical combination of nsaid and prostaglandin compound

Publications (1)

Publication Number Publication Date
NZ582327A true NZ582327A (en) 2012-08-31

Family

ID=39863290

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ582327A NZ582327A (en) 2007-07-03 2008-07-03 Pharmaceutical combination of nsaid and prostaglandin compound

Country Status (13)

Country Link
US (1) US20090012165A1 (enExample)
EP (1) EP2175861B1 (enExample)
JP (1) JP2010532314A (enExample)
KR (1) KR20100056445A (enExample)
CN (1) CN101686984A (enExample)
AU (1) AU2008271982B2 (enExample)
BR (1) BRPI0812838A2 (enExample)
CA (1) CA2691107A1 (enExample)
IL (1) IL202765A0 (enExample)
NZ (1) NZ582327A (enExample)
RU (1) RU2010103505A (enExample)
SG (1) SG182236A1 (enExample)
WO (1) WO2009005172A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2205642B1 (en) 2007-11-02 2016-01-27 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
JP2011032262A (ja) * 2009-06-30 2011-02-17 Sucampo Ag Ｎｓａｉｄの長期使用のための医薬組成物
US20110034424A1 (en) * 2009-06-30 2011-02-10 Sucampo Ag Method for the long term nsaid use
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
BR112012026542A2 (pt) 2010-04-16 2016-07-12 Momenta Pharmaceuticals Inc abordagem seletiva de tecido
AU2011268470B2 (en) 2010-06-17 2017-02-02 Momenta Pharmaceuticals, Inc. Methods and compositions for promoting hair growth
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US10016449B2 (en) 2013-05-28 2018-07-10 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3781429A (en) * 1972-09-29 1973-12-25 American Cyanamid Co Method of inhibiting ulcerogenesis induced by non-steroidal anti-inflammatory agents
CA1041012A (en) * 1973-07-10 1978-10-24 American Home Products Corporation Method of reducing the incidence of gastrointestinal side effects during the treatment of inflammatory conditions with antiinflammotory drugs and compositions therefor
ZA748216B (en) * 1974-01-28 1976-01-28 Upjohn Co Medical treatment with prostaglandins
US3928588A (en) * 1974-02-22 1975-12-23 Upjohn Co Method of reducing the undesirable gastrointestinal effects of prostaglandin synthetase inhibitors
US5380709A (en) * 1987-01-28 1995-01-10 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5225439A (en) * 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
JPH0688966B2 (ja) * 1987-01-28 1994-11-09 株式会社アールテック・ウエノ プロスタグランジンｅ類およびそれを含む抗潰瘍剤
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5317032A (en) * 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
NZ253631A (en) * 1992-06-30 1997-02-24 Procter & Gamble Pharma Phosphonate or nsaid pharmaceutical compositions for treating arthritis
AU9062998A (en) * 1997-09-11 1999-03-29 Nycomed Danmark A/S Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (nsaids)
US5876034A (en) 1997-12-17 1999-03-02 Stafford; James R. Sporting fishing board game
SE9803761D0 (sv) * 1998-11-04 1998-11-04 Synphora Ab Method to avoid increased iridial pigmentation during prostaglandin treatment
US6183779B1 (en) * 1999-03-22 2001-02-06 Pharmascience Inc. Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
ATE402925T2 (de) 1999-10-15 2008-08-15 Sucampo Ag Neue zusammensetzung enthaltend eine bicyclische verbindung und ein glycerid
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
JP4786866B2 (ja) * 2001-08-31 2011-10-05 スキャンポ・アーゲー クロライドチャンネルオープナーとしてのプロスタグランジンアナログ
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) * 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
JP4889219B2 (ja) * 2002-12-27 2012-03-07 スキャンポ・アーゲー 腹部不快感の処置のためのプロスタグランジン誘導体
KR101466980B1 (ko) * 2005-04-12 2014-12-01 수캄포 아게 위장 장애 치료를 위한 프로스타글란딘 화합물과 양성자펌프 억제제의 병용
US7893107B2 (en) * 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
CA2657606A1 (en) * 2006-03-08 2007-09-13 Cortria Corporation Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries
US7868045B2 (en) * 2006-09-06 2011-01-11 Sucampo Ag Method for promoting gastrointestinal bicarbonate secretion
JP2010513551A (ja) * 2006-12-18 2010-04-30 アラーガン インコーポレイテッド 胃腸疾患の治療方法および組成物

Also Published As

Publication number Publication date
BRPI0812838A2 (pt) 2014-12-09
CN101686984A (zh) 2010-03-31
EP2175861A1 (en) 2010-04-21
EP2175861B1 (en) 2014-08-20
SG182236A1 (en) 2012-07-30
KR20100056445A (ko) 2010-05-27
JP2010532314A (ja) 2010-10-07
US20090012165A1 (en) 2009-01-08
IL202765A0 (en) 2010-06-30
AU2008271982B2 (en) 2014-04-24
AU2008271982A1 (en) 2009-01-08
WO2009005172A1 (en) 2009-01-08
CA2691107A1 (en) 2009-01-08
RU2010103505A (ru) 2011-08-10

Similar Documents

Publication Publication Date Title
JP2009530288A5 (enExample)
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
MY136796A (en) Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection
CY1111721T1 (el) Ακυλαμινοπυραζολια ως αναστολεις fgfr
NZ601529A (en) Tapentadol compositions
UA97795C2 (uk) Дейтеровані похідні катехоламіну і медикаменти, що містять згадані сполуки
EA201301078A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
IL189546A0 (en) Therapy for the treatment of disease
EA200802329A1 (ru) Производные триазола ii
LU92692I2 (fr) Ibrutinib, ou un sel pharmaceutiquement acceptablede celui-ci
TN2009000399A1 (fr) Procedes de traitement impliquant l'inhibition de pi3k-alpha au moyen d'inhibiteurs de type quinaxoline
NO20084362L (no) Difenylazetidinon derivater inneholdende kolesterol absorbsjonsinhibitor aktivitet
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
TN2011000240A1 (en) Hsp90 inhibitors for therapeutic treatment
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure
TW200612922A (en) Inhibitors of hsp90
BRPI0415187A (pt) composição, método para matar bactérias, e, usos de composição e de bacteriófago
Ferrario et al. Enhancement of photodynamic therapy by 2, 5-dimethyl celecoxib, a non-cyclooxygenase-2 inhibitor analog of celecoxib
MX2009009230A (es) Uso de silodosina en una administracion diaria para tratar hiperplasia prostatica benigna.
CA2765453A1 (en) Medicament for the long term nsaid use
Hahn et al. Role of cyclooxygenase-2 in pathogenesis and prevention of colorectal cancer
AR063228A1 (es) Antinflamatorios no esteroideos contra la tos
JP2005506371A5 (enExample)
BR0111900A (pt) Uso de um antagonista do receptor do tipo 1 da angiotensina ii, formulação farmacêutica, e, métodos para o tratamento de uma condição de cefaléia vascular e para o tratamento de enxaqueca

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 03 JUL 2015 BY HENRY HUGHES

Effective date: 20130122

LAPS Patent lapsed